{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:49:06Z","timestamp":1792882146471,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Karuna Therapeutics"},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Xanomeline and trospium chloride (formerly KarXT) is a muscarinic M1 and M4 receptor agonist recently approved for the treatment of schizophrenia in adults. Unlike all previously approved antipsychotics, it does not directly block dopamine D2 receptors. Given its novel mechanism of action, understanding patients\u2019 subjective treatment experiences, including perceived symptom changes, is clinically important.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a qualitative study embedded within a larger 52-week open-label long-term safety study that investigated patient perspectives on xanomeline\/trospium monotherapy in clinically stable outpatients transitioned from previous antipsychotic treatments. A subsample completed up to 2 semi-structured interviews to explore their experience\u2014favorable or unfavorable\u2014approximately 6\u00a0weeks (n\u2009=\u200970) and 6\u00a0months (n\u2009=\u200947) post-initiation. Thematic analysis was applied to interview transcripts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At study entry, most participants reported symptoms despite ongoing antipsychotic treatment, including positive (auditory hallucinations, &amp;gt;80%), negative (low motivation, &amp;gt;70%), and cognitive (trouble concentrating, &amp;gt;70%) symptoms. Over 60% reported meaningful improvement in one or more symptoms within 6\u00a0weeks of starting xanomeline\/trospium, increasing to about 80% by 6\u00a0months. Less than 10% reported symptom worsening at either time point. Participants described these improvements as personally meaningful, with notable benefits in daily functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Participants entered this study with various persistent, burdensome schizophrenia symptoms despite ongoing treatment. Most experienced substantial and sustained symptom relief for up to 6\u00a0months after initiating xanomeline\/trospium treatment. These qualitative findings highlight xanomeline\/trospium\u2019s potential to provide meaningful relief across multiple symptom domains and support functional recovery. A companion report explores quality of life and medication satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schizbullopen\/sgag002","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:41:59Z","timestamp":1770295319000},"source":"Crossref","is-referenced-by-count":2,"title":["A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms"],"prefix":"10.1093","volume":"7","author":[{"given":"William P","family":"Horan","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["United States"]},{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California , Los Angeles, CA 90095 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Saucier","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric Inc. , Johnston, Rhode Island 02919 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-5871","authenticated-orcid":false,"given":"Peter J","family":"Weiden","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University , Stony Brook, NY 11794 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Claxton","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-309X","authenticated-orcid":false,"given":"Stephen R","family":"Marder","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California , Los Angeles, CA 90095 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April M","family":"Foster","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric Inc. , Johnston, Rhode Island 02919 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Sauder","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"LaGasse","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric Inc. , Johnston, Rhode Island 02919 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sloan","family":"Rucker","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric Inc. , Johnston, Rhode Island 02919 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Jackson","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric Inc. , Johnston, Rhode Island 02919 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej","family":"Patel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G","family":"Sonnenberg","sequence":"additional","affiliation":[{"name":"Uptown Research Institute , Chicago, IL 60640,","place":["United States"]},{"name":"Department of Psychiatry and Biobehavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Kaul","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026031906262993800_ref1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra1801490","article-title":"Psychotic disorders","volume":"379","author":"Lieberman","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031906262993800_ref2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031906262993800_ref3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"2026031906262993800_ref4","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026031906262993800_ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240076","article-title":"The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials","volume":"182","author":"Horan","year":"2025","journal-title":"Am J Psychiatry"},{"key":"2026031906262993800_ref6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","article-title":"Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials","volume":"10","author":"Horan","year":"2024","journal-title":"Schizophr Res"},{"key":"2026031906262993800_ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2023-002719","article-title":"Principles and elements of patient-centredness in mental health services: a thematic analysis of a systematic review of reviews","volume":"13","author":"Khosravi","year":"2024","journal-title":"BMJ Open Qual"},{"key":"2026031906262993800_ref8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jpm.12288","article-title":"What is it like to take antipsychotic medication? A qualitative study of patients with first-episode psychosis","volume":"23","author":"Gray","year":"2016","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"2026031906262993800_ref9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1348\/147608304322874236","article-title":"The quest for well-being: a qualitative study of the experience of taking antipsychotic medication","volume":"77","author":"Carrick","year":"2004","journal-title":"Psychol Psychother"},{"key":"2026031906262993800_ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2304-3","article-title":"Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid","volume":"19","author":"Kaar","year":"2019","journal-title":"BMC Psychiatry"},{"key":"2026031906262993800_ref11","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbae104","article-title":"Making sense of recovery from First psychosis with antipsychotic medication: a qualitative phenomenological study","author":"Dijkstra","year":"2024","journal-title":"Schizophr Bull"},{"key":"2026031906262993800_ref12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12888-023-04746-4","article-title":"Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups","volume":"23","author":"Doane","year":"2023","journal-title":"BMC Psychiatry"},{"key":"2026031906262993800_ref13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.apnu.2020.06.002","article-title":"A qualitative study of medication adherence amongst people with schizophrenia","volume":"34","author":"Clifford","year":"2020","journal-title":"Arch Psychiatr Nurs"},{"key":"2026031906262993800_ref14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/09638237.2017.1370637","article-title":"The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample","volume":"27","author":"Morant","year":"2018","journal-title":"J Ment Health Aug"},{"key":"2026031906262993800_ref15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijnurstu.2018.05.003","article-title":"A narrative meta-synthesis of how people with schizophrenia experience facilitators and barriers in using antipsychotic medication: implications for healthcare professionals","volume":"85","author":"Salzmann-Erikson","year":"2018","journal-title":"Int J Nurs Stud Sep"},{"key":"2026031906262993800_ref16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/archgenpsychiatry.2012.652","article-title":"From perception to functional outcome in schizophrenia: modeling the role of ability and motivation","volume":"69","author":"Green","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"2026031906262993800_ref17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/wps.20624","article-title":"Nonsocial and social cognition in schizophrenia: current evidence and future directions","volume":"18","author":"Green","year":"2019","journal-title":"World Psychiatry Jun"},{"key":"2026031906262993800_ref18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/wps.20385","article-title":"The current conceptualization of negative symptoms in schizophrenia","volume":"16","author":"Marder","year":"2017","journal-title":"World Psychiatry"},{"key":"2026031906262993800_ref19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjc.12248","article-title":"Understanding individuals' subjective experiences of negative symptoms of schizophrenia: a qualitative study","volume":"59","author":"Butcher","year":"2020","journal-title":"Br J Clin Psychol"},{"key":"2026031906262993800_ref20","doi-asserted-by":"crossref","first-page":"sgad012","DOI":"10.1093\/schizbullopen\/sgad012","article-title":"Qualitative analysis of the content validity of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) in schizophrenia: a multi-stakeholder perspective","volume":"4","author":"Horan","year":"2023","journal-title":"Schizophr Bull Open"},{"key":"2026031906262993800_ref21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cpp.1878","article-title":"The experience of cognitive impairment in people with psychosis","volume":"22","author":"Wood","year":"2015","journal-title":"Clin Psychol Psychother"},{"key":"2026031906262993800_ref22","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgag003","article-title":"A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride For Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction","author":"Weiden","year":"2026","journal-title":"Schizophr Bull."},{"key":"2026031906262993800_ref23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia","volume":"416","author":"Haro","year":"2003","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2026031906262993800_ref24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardization","volume":"155","author":"Kay","year":"1989","journal-title":"Br J Psychiatry"},{"key":"2026031906262993800_ref25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-61779-458-2_3","article-title":"Qualitative versus quantitative methods in psychiatric research","volume":"829","author":"Razafsha","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2026031906262993800_ref26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40271-024-00726-2","article-title":"Qualitative in-trial interviews: methods, challenges, and best practice","volume":"18","author":"Williamson","year":"2025","journal-title":"Patient"},{"key":"2026031906262993800_ref27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/B978-0-12-405170-6.00006-3","volume-title":"Clinical Trial Design Challenges in Mood Disorders","author":"Berk","year":"2015"},{"key":"2026031906262993800_ref28","volume-title":"Handbook of Practical Program Evaluation","author":"Adams","year":"2015"},{"key":"2026031906262993800_ref29","volume-title":"Discovery of Grounded Theory: Strategies for Qualitative Research","author":"Glaser","year":"1999"},{"key":"2026031906262993800_ref30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/160940690600500304","article-title":"Grounded theory and sensitizing concepts","volume":"5","author":"Bowen","year":"2006","journal-title":"Int J Qual Methods"},{"key":"2026031906262993800_ref31","first-page":"83","article-title":"Grounded theory and the constant comparative method: valid research strategies for educators","volume":"3","author":"Kolb","year":"2012","journal-title":"J Emerg Trends Educ Res Policy Stud"},{"key":"2026031906262993800_ref32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"2026031906262993800_ref33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1744987117741667","article-title":"Directed qualitative content analysis: the description and elaboration of its underpinning methods and data analysis process","volume":"23","author":"Assarroudi","year":"2018","journal-title":"J Res Nurs Feb"},{"key":"2026031906262993800_ref34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","article-title":"Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development","volume":"7","author":"Turner-Bowker","year":"2018","journal-title":"Value Health"},{"key":"2026031906262993800_ref35","doi-asserted-by":"crossref","first-page":"e0232076","DOI":"10.1371\/journal.pone.0232076","article-title":"A simple method to assess and report thematic saturation in qualitative research","volume":"15","author":"Guest","year":"2020","journal-title":"PLoS One"},{"key":"2026031906262993800_ref36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eurpsy.2011.01.012","article-title":"Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia","volume":"27","author":"Karow","year":"2012","journal-title":"Eur Psychiatry Aug"},{"key":"2026031906262993800_ref37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eurpsy.2011.01.013","article-title":"Remission as perceived by people with schizophrenia, family members and psychiatrists","volume":"27","author":"Karow","year":"2012","journal-title":"Eur Psychiatry Aug"},{"key":"2026031906262993800_ref38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.31887\/DCNS.2010.12.3\/mlambert","article-title":"Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later","volume":"12","author":"Lambert","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"key":"2026031906262993800_ref39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.psychres.2018.04.005","article-title":"Understanding the course of persistent symptoms in schizophrenia: longitudinal findings from the pattern study","volume":"267","author":"Haro","year":"2018","journal-title":"Psychiatry Res"},{"key":"2026031906262993800_ref40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2015.09.001","article-title":"Understanding the impact of persistent symptoms in schizophrenia: cross-sectional findings from the pattern study","volume":"169","author":"Haro","year":"2015","journal-title":"Schizophr Res"},{"key":"2026031906262993800_ref41","doi-asserted-by":"crossref","first-page":"1421554","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M(1) and M(4) receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front Psychiatry"}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgag002\/66781608\/sgag002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag002\/66781608\/sgag002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag002\/66781608\/sgag002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:26:35Z","timestamp":1773915995000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgag002\/8464190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgag002","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"sgag002"}}